Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K W Bair

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Anticancer Research|January 1, 1997
The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833P H Ehrlich, Z A Moustafa, A E Archinal-Mattheis, et al.
Oncology Research|January 1, 1995
Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoproteinA Archinal-Mattheis, R W Rzepka, T Watanabe, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Identification of E2F-1/Cyclin A antagonistsS K Sharma, T M Ramsey, Y N Chen, et al.
Journal of Medicinal Chemistry|March 26, 1999
Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1)P Ettmayer, D France, J Gounarides, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 1999
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonistsY N Chen, S K Sharma, T M Ramsey, et al.
The Journal of Organic Chemistry|March 23, 2001
Bengamides revisited: new structures and antitumor studiesZ Thale, F R Kinder, K W Bair, et al.
Anti-Cancer Drugs|August 1, 1991
Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalatorsK A Havlin, J G Kuhn, J B Craig, et al.
Cancer Research|December 1, 1990
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose scheduleD D Von Hoff, J G Kuhn, K A Havlin, et al.
The Journal of Organic Chemistry|April 13, 2001
Total syntheses of bengamides B and EF R Kinder, S Wattanasin, R W Versace, et al.
Journal of Medicinal Chemistry|October 19, 2001
Synthesis and antitumor activity of ester-modified analogues of bengamide BF R Kinder, R W Versace, K W Bair, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Anticancer Research|January 1, 1997
The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833P H Ehrlich, Z A Moustafa, A E Archinal-Mattheis, et al.
Oncology Research|January 1, 1995
Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoproteinA Archinal-Mattheis, R W Rzepka, T Watanabe, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
Identification of E2F-1/Cyclin A antagonistsS K Sharma, T M Ramsey, Y N Chen, et al.
Journal of Medicinal Chemistry|March 26, 1999
Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1)P Ettmayer, D France, J Gounarides, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 1999
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonistsY N Chen, S K Sharma, T M Ramsey, et al.
The Journal of Organic Chemistry|March 23, 2001
Bengamides revisited: new structures and antitumor studiesZ Thale, F R Kinder, K W Bair, et al.
Anti-Cancer Drugs|August 1, 1991
Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalatorsK A Havlin, J G Kuhn, J B Craig, et al.
Cancer Research|December 1, 1990
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose scheduleD D Von Hoff, J G Kuhn, K A Havlin, et al.
The Journal of Organic Chemistry|April 13, 2001
Total syntheses of bengamides B and EF R Kinder, S Wattanasin, R W Versace, et al.
Journal of Medicinal Chemistry|October 19, 2001
Synthesis and antitumor activity of ester-modified analogues of bengamide BF R Kinder, R W Versace, K W Bair, et al.
Pageof 2